2-Day Virtual Seminar on Best Practices for Import and Export Control and Customs Compliance

Recorded Webinar | Casper Uldriks | From: Mar 31, 2021 - To: Dec 31, 2021

Training Options & Pricing

Error Conference Exists In Wish-list.

Congrats Conference Added In Wish-list.

Recording
   $1099  
DVD
   $1119  
Recording + DVD
   $1289  
Transcript (Pdf)
   $1099  
Recording & Transcript (Pdf)
   $1279  
DVD & Transcript (Pdf)
   $1289  


Order Form

2-Day Virtual Seminar on Best Practices for Import and Export Control and Customs Compliance During and After COVID 19

FDA’s import and export programs are complex, detailed, and undergo changes without notice to the public.  The FDA’s and CBP’s new import and enforcement programs operate with remarkably efficient software systems that can leave a firm scrambling for a resolution and end up suffering the expensive consequences of detention.  The information database used by the FDA includes extensive information from foreign suppliers.  If that is not in order, your shipment will not be permitted entry, in some cases even before the products can be loaded onto the vessel in a foreign port or before it arrives at the U.S. port.

Foreign establishments are subject to the same manufacturing regulations as U.S. firms.  There are inherent problems with foreign commerce, such as language and cultural differences.  If a foreign firm’s manufacturing operation or its products fail any criteria, detention, or even worse, a refusal, becomes your next crisis.  If your product is detained, you must know how to try and resolve the problem with the FDA.  You have only ten days to figure out your plan and have FDA agree, which is not a given. On day 11, your product must either be destroyed or exported.  

FDA offers special programs to automatically release entries provided pre-qualification criteria are met.  This is especially valuable to importers of perishable goods. 

Import/export requirements can be confusing and costly if you do not understand the legal requirements.  You need clarity, accurate knowledge, and solid business procedures to succeed.

Areas Covered in the Session:-

  • Impact of COVID-19
  • FDA’s legal authority and evidence threshold
  • Information required by FDA, CBP, and the U.S. Census Bureau
  • FDA’s entry evaluation procedures 
  • Foreign supplier requirements
  • Products returned for repair
  • Imports of bulk pharmaceuticals, investigational products, and research products
  • Export requirements and certificates
  • Import-for-export requirements

Why you Should Attend?

  • Identify and mitigate the impact factors of COVID-19 
  • Understand how the FDA’s and the CBP’s legal and administrative requirements intersect such as the Affirmation of Compliance and ACE.
  • You can understand FDA’s legal requirements and somewhat esoteric policies
  • Understand FDA’s internal procedures for import operations
  • Learn how to mitigate and resolve import detentions
  • Learn how to avoid common problems
  • Develop practical ways to improve your import and export business
  • Learn how to interact with FDA and follow their procedures
  • Learn what happens to you if a foreign supplier is in trouble with FDA
  • Understand FDA export rules

Who Will Benefit?

  • Business Planning Executives
  • Regulatory Directors
  • In-house Legal Counsel and Contract Specialists
  • Venture Capitalists
  • Business acquisition Managers
  • Owners of New or Developing Import/Export Firms
  • International Trade and Logistics Managers
  • Import Brokers
  • Investors
  • Sales Managers

Casper Uldriks

Casper (Cap) Uldriks, through his firm "Encore Insight LLC," brings over 32 years of experience from the FDA. He specialized in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health.

He developed enforcement actions and participated in the implementation of new statutory requirements. His comments are candid, straightforward and of practical value. He understands how FDA thinks, how it operates and where it is headed.

Based on his exceptionally broad experience and knowledge, he can synthesize FDA's domestic and international operational programs, institutional policy and thicket of legal variables into a coherent picture. Professional credentials: JD - Suffolk University, licensed in Massachusetts and the District of Columbia; M.Div in psychology - Boston University with internship through Harvard University.